AzTrials
AzTrials

Acute CholangitisNCT02601417

The Necessity of Bile Cultures in Patients With Acute Cholangitis

A study testing Ignoring result of bile culture in people with Acute Cholangitis, run by Seoul National University Hospital at 1 site in South Korea.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Acute cholangitis with obstructive jaundice is a condition which needs biliary drainage and appropriate antibiotics. Bile culture is an optional laboratory test according to 2013, 2018 Tokyo guideline, but the clinical significance is yet unproven. Read more about this study

Who is it for?
Ages 20 years and older
Conditions the study is for
Acute Cholangitis
What is being tested?
Ignoring result of bile culture
Could I receive a placebo?
No, everyone receives an active treatment
How many people
440 participants
Where
1 siteSouth Korea
Study dates
27 Aug 2015to 30 Jul 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

The inclusion criteria

(1) patients aged ≥20 years with suspected or confirmed acute cholangitis according to the 2013 and 2018 Tokyo guidelines

The exclusion criteria

  1. inability to provide informed consent
  2. no evidence of acute cholangitis diagnostics as per the guidelines
  3. development of organ failure before random allocation or organ failure by non-cholangitis causes
  4. undergoing bile culture tests after the onset of organ failure
  5. failure to have bile or blood culture tests
  6. patients who were already administered antibiotics for other conditions
  7. unsuccessful PTBD insertion
  8. failure to achieve complete bile drainage via PTBD

Trial locations and contacts

1 site in 1 country.

South Korea1 site
  • Seoul National University Hospital

    Seoul, 110-744

Other trials in South Korea

About this study

Acute cholangitis with obstructive jaundice is a condition which needs biliary drainage and appropriate antibiotics. Bile culture is an optional laboratory test according to 2013, 2018 Tokyo guideline, but the clinical significance is yet unproven. And its results might indicate less information of the true pathogen regarding normal flora. Previous study conducted at our institute found drug-resistant pathogens identified in bile culture had no impact on the outcome. So the investigators are conducting a multicenter randomized controlled trial comparing groups which considers both blood and bile culture as control and which considers only blood culture as trial group in order to prove bile culture provides no additional helpful clinical information.

Read the detailed description

The investigators conducted a nationwide, prospective, multicenter, subject blinded, noninferiority RCT. Patients with acute cholangitis who met the specific inclusion criteria were enrolled. All the participants underwent a percutaneous transhepatic biliary drainage (PTBD) procedure to provide adequate drainage, and both bile and blood cultures were collected. A culture study was performed after obtaining the initial bile from the bile duct assessment during PTBD insertion. In this study, the patients who were conducted endoscopic retrograde cholangiopancreatography (ERCP) and biliary drainage were excluded to avoid unintended contamination by normal flora of gastrointestinal tract.

Initially, empirical broad-spectrum antibiotics, including metronidazole combined with third-generation cephalosporins or quinolones were administered for treating acute cholangitis. All participants provided informed consent after explaining the study details. Participants who consented to participate were then randomized.

The investigators recruited patients aged ≥20 years with suspected or confirmed acute cholangitis according to the 2013 and 2018 Tokyo guidelines. The exclusion criteria were (1) inability to provide informed consent, (2) no evidence of acute cholangitis diagnostics as per the guidelines, (3) development of organ failure before random allocation or organ failure by non-cholangitis causes, (4) undergoing bile culture tests after the onset of organ failure, (5) failure to have bile or blood culture tests, (6) patients who were already administered antibiotics for other conditions, (7) unsuccessful PTBD insertion, and (8) failure to achieve complete bile drainage via PTBD.

Empirical antibiotic therapy was initially conducted for both groups of patients. In the control group, the initial antibiotic regimen was maintained if both blood and bile cultures were negative or if all identified organisms were sensitive to empirical treatment. However, the empirical antibiotics were switched to appropriate antibiotics considering the results from blood and bile cultures if any organism demonstrated resistance. In experimental group, the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group.

Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians.

The investigators carried out a per-protocol analysis that excluded patients who had received antibiotics prior to PTBD, which could have altered the microbial profile, those with lethal adverse events before the confirmation of blood or bile culture results, and those who had been administered changed antibiotics for infectious diseases other than acute cholangitis.

Student's t-test was used to analyze continuous variables with normal distribution, Mann-Whitney U-test was performed otherwise. Categorical variables were assessed with the chi-square test or Fisher's exact test. A p-value of ≤0.05 indicated significant differences, and the respective variables were regarded as covariates for adjustment in each analysis. Student's t-test and Mann-Whitney U-test were used to compare mortality and hospital stay duration. All the tests were two-sided, and a p-value of <0.05 was regarded as statistically significant. In the analyses of binary outcomes, the results are presented as point estimates for the between-group differences in the proportion of patients. The two-sided 95% confidence interval (CI) for these differences was calculated using the Wald method.

Being tested
Ignoring result of bile culture
Keywords
Cholangitis, Bile culture, percutaneous transhepatic biliary drainage
Medical subject headings
Cholangitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ignoring result of bile cultureOther

    the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group

Study groups in NCT02601417
Study groupRoleWhat they receive
Antibiotics change is based on both blood and bile culturesNo interventionEmpirical antibiotic therapy was initially conducted for patients. In the control group, the initial antibiotic regimen was maintained if both blood and bile cultures were negative or if all identified organisms were sensitive to empirical treatment. However, the empirical antibiotics were switched to appropriate antibiotics considering the results from blood and bile cultures if any organism demonstrated resistance. Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians.
Antibiotics change is based only on the blood cultureExperimentalEmpirical antibiotic therapy was initially conducted for patients. In experimental group, the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group. Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians.
Receives: Other: Ignoring result of bile culture

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Organ Failure

    Shock, AKI, altered mentality, Acute respiratory distress

    Measured: during hospitalization and empirical antibiotic administration. (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)

Secondary outcomes (3)
  1. Hospital days

    The duration of hospital stay covered the period from randomization to discharge for the management of acute cholangitis

    Measured: through study completion, an average of 1 month

  2. Re-intervention for biliary drainage

    The frequency of reintervention for biliary drainage was the proportion of patients undergoing additional procedures during the study period.

    Measured: through study completion, an average of 1 month

  3. Mortality

    Mortality rate was the proportion of patients experiencing death during the study period.

    Measured: through study completion, an average of 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Nov 2015 (estimated)
  2. Study start27 Aug 2015
  3. Primary completion20 Mar 2024
  4. Study completion30 Jul 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
440 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02601417
Sponsor's protocol ID
2015-1452
Status last verified
May 2024
First submitted
27 Aug 2015
Last updated
30 May 2024
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Ignoring result of bile culture in people with Acute Cholangitis, run by Seoul National University Hospital at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Organ Failure (time frame: during hospitalization and empirical antibiotic administration. (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in